Arabic Arabic English English French French German German
dark

Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients

AZ’s combo treatment reduced the risk of disease progression or death by 28% compared to chemotherapy alone Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Results for the inaugural QiC Dermatology Awards 2021 in association with Dermatology in practice announced!

Next Post

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

Related Posts
Total
0
Share